You are here: All Products  > Innovent's PD-1 Inhibitor Meets Endpoint as First-Line Gastric Cancer Therapy

Innovent's PD-1 Inhibitor Meets Endpoint as First-Line Gastric Cancer Therapy

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products